Insights

Why Moderna Stock Jumped Today

What happened
Shares of Moderna (NASDAQ: MRNA) rose 5.8% on Wednesday after the pharmaceutical leader delivered an impressive first-quarter report. 
So what 
Moderna’s revenue soared 213% to $6.1 billion. The company’s net income, in turn, tripled to $3.7 billion, or $8.58 per share. Those figures were significantly above Wall Street’s estimates. Analysts had forecast revenue and earnings per share of $4.6 billion and $5.21, respectively. 
Moderna’s vaccine, Spikevax, has become a key tool in the battle against COVID-19. The biotech generated $5.9 billion in vaccine sales in the first quarter, and management expects a total of $21 billion in 2022.
Image source: Getty images.

Now what
Booster shots are likely to be a key source of future sales for Moderna. “The virus is mutating to become more and more infectious, and there’s waning immunity,” CEO Stéphane Bancel said during an interview on CNBC. “It is going to be really important to boost people in the fall with a better-adapted vaccine, which is what we’re working toward.”
Vaccines for children are expected to be another source of growth. Moderna has requested Emergency Use Authorization for its COVID vaccine in kids as young as 6 months old and hopes to receive the authorization from the Food and Drug Administration by June. 
Additionally, vaccine sales have allowed Moderna to build a fortresslike balance sheet. Its cash and investments grew to more than $19.3 billion as of March 31. The company intends to use some of this capital to fund its extensive research and development program, while also rewarding shareholders with stock buybacks.
Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy. –

What happened

Shares of Moderna (NASDAQ: MRNA) rose 5.8% on Wednesday after the pharmaceutical leader delivered an impressive first-quarter report. 

So what 

Moderna’s revenue soared 213% to $6.1 billion. The company’s net income, in turn, tripled to $3.7 billion, or $8.58 per share. Those figures were significantly above Wall Street’s estimates. Analysts had forecast revenue and earnings per share of $4.6 billion and $5.21, respectively. 

Moderna’s vaccine, Spikevax, has become a key tool in the battle against COVID-19. The biotech generated $5.9 billion in vaccine sales in the first quarter, and management expects a total of $21 billion in 2022.

Image source: Getty images.

Now what

Booster shots are likely to be a key source of future sales for Moderna. “The virus is mutating to become more and more infectious, and there’s waning immunity,” CEO Stéphane Bancel said during an interview on CNBC. “It is going to be really important to boost people in the fall with a better-adapted vaccine, which is what we’re working toward.”

Vaccines for children are expected to be another source of growth. Moderna has requested Emergency Use Authorization for its COVID vaccine in kids as young as 6 months old and hopes to receive the authorization from the Food and Drug Administration by June. 

Additionally, vaccine sales have allowed Moderna to build a fortresslike balance sheet. Its cash and investments grew to more than $19.3 billion as of March 31. The company intends to use some of this capital to fund its extensive research and development program, while also rewarding shareholders with stock buybacks.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US & HK* Trades. Click Here!